Abstract
assays for TH revealed a low immunoreactivity (expressed as number of cells) in the striatum of the 6-OHDA group (8.5±0.992) and this was reversed in the 6-OHDA+SEMU40 group (110.3±9.025). On the other hand, higher immunoreactivities for COX-2, iNOS and TNF-alpha were demonstrated in the 6-OHDA group (COX-2: 256.3±9.677; iNOS: 78.0±2.887; TNF-alpha: 245.0±9.859) as related to SO (COX-2: 63.2±3.400; iNOS: 55.7±2.512; TNF-alpha: 27.2±1.922) and 6-OHDA+SEMU20 (COX-2: 80.2±2.676; iNOS: 73.2±2.120; TNF-alpha: 83.5±3.793) or 6-OHDA+SEMU40 (COX-2: 81.7±3.442; iNOS: 50.7±3.040; TNF-alpha: 96.2±4.453) groups. In conclusion, we showed for the first time beneficial effects of SEMU on the 6-OHDA-induced model of PD, pointing out to the potential usefulness of M. urundeuva as an adjuvant drug for PD treatment and stimulating translational studies focusing on the inclusion of this species in clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
